Precision BioSciences hit another major milestone. ✅ PBGENE-HBV, our wholly owned in vivo gene editing program for chronic hepatitis B, has received Fast Track designation from the FDA—unlocking new potential for accelerated development and long-term value! 🌍 Global Phase 1

Last week, Michael Amoroso, Chief Executive Officer, and Cassie Gorsuch, PhD, Chief Scientific Officer, spoke in a fireside chat at the Citizens Life Sciences Conference in New York. Want to hear what they had to say? Visit loom.ly/msMpNBg #GeneEditing #Biotech #DTIL

Precision BioSciences announced its Q1 2025 earnings and provided a business update! 🧬 PBGENE-HBV: ✔️ Fast Track designation ✔️ Encouraging safety + early efficacy data ✔️ Now cleared for trials in 5 countries ✔️ Clinical data presented at EASL - safe after two doses 💪

📸 On the ground at #ASGCT2025 — the Precision BioSciences team proudly presented preclinical data for PBGENE-DMD, our first-in-class in vivo gene editing therapy for the majority of Duchenne muscular dystrophy (DMD) patients. 🧬 Using our proprietary ARCUS platform, PBGENE-DMD

☀️ Summer is starting, but the Precision team isn't slowing down! Gary Owens, Program Leader for PBGENE-DMD at Precision BioSciences, recently attended and presented at the CureDuchenne FUTURES National Conference. With compelling preclinical evidence, PBGENE-DMD, Precision's

We're back at the Jefferies Global Healthcare Conference! Michael Amoroso, Chief Executive Officer, and Cassie Gorsuch, PhD, Chief Scientific Officer, joined Maury Raycroft for a fireside chat. Want to listen? loom.ly/mAYIYpU #GeneEditing #DMD #PrecisionBioSciences

We’re proud to share that the FDA has granted Rare Pediatric Disease Designation to PBGENE-DMD, our ARCUS gene editing therapy for Duchenne muscular dystrophy. Cindy Atwell, Chief Development & Business Officer, shares what this milestone means for our team and the DMD

Precision BioSciences announced its Q2 2025 earnings and provided a business update! CFO, Alex Kelly, tells you what you need to know. Watch the full video here, youtu.be/DoTt8EzSRMI Read the full press release, loom.ly/njH7XSo #GeneEditing #Biotech $DTIL

Precision BioSciences announced a Phase 1 safety and efficacy update for the lowest dose level in ELIMINATE-B, a first-in-human evaluation of PBGENE-HBV for chronic Hepatitis B. Here's what you should know! Read the full PR, loom.ly/IqsoN94 #GeneEditing #HBV

Standing together in red for #WorldDuchenneAwarenessDay, the Precision BioSciences team proudly supports the global fight against Duchenne muscular dystrophy and reaffirms our commitment to advancing hope through groundbreaking gene editing solutions. Learn more about

We're pleased to announce that Mark Sulkowski, M.D., Professor of Medicine at the Johns Hopkins University School of Medicine and a renowned expert in hepatic and infectious diseases, has expanded his advisory role with Precision BioSciences. In the newly created role, Head

Emily Harrison, Ph.D., Head of Translational Science at Precision, presents data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV with the community at this year’s 6th International Coalition to Eliminate HBV Cure Symposium. We believe the clinical profile we have observed so

This week, Precision BioSciences announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society on Friday, October 10th in Vienna, Austria! Cassie Gorsuch, Ph.D., Chief Scientific Officer, will present these encouraging

We’re excited to announce the opening of Precision BioSciences’ first U.S. clinical trial site for the ELIMINATE-B Phase 1 study, now actively recruiting patients at Massachusetts General Hospital in Boston. This marks a major milestone in Precision’s mission to develop a

Cassie Gorsuch, PhD, Chief Scientific Officer at Precision BioSciences, represented our team and shared our latest progress at this year’s 30th Annual International Congress of the World Muscle Society. Cassie presented new long-term preclinical data for PBGENE-DMD, showcasing

We’re proud to share that our ARCUS® platform is featured in a new peer-reviewed publication in Nucleic Acids Research, further demonstrating the broad and versatile power of our genome editing technology. The manuscript highlights how ARCUS nucleases can achieve high-frequency,

Join us on Monday, November 3, at 11 am ET for a Precision BioSciences Virtual Symposium! The company's lead muscle program, PBGENE-DMD, represents the first in vivo gene editing therapy designed to restore functional dystrophin protein and improve long-term muscle function for

Precision BioSciences was proud to join leaders from across the genetic medicines field at Chardan’s 9th Annual Genetic Medicines Conference in New York City. Connecting with experts, investors, and innovators in this space is vital as we advance our mission to deliver

Precision BioSciences announced its Q3 2025 earnings and provided a business update! CFO, Alex Kelly, tells you what you need to know. Read the full press release, loom.ly/eUsgr8k #GeneEditing #Biotech $DTIL

Precision BioScience is proud to share new data at #AASLD2025 for PBGENE-HBV, our first-in-class gene editing therapy for chronic hepatitis B, presented by Man-Fung Yuen, MBBS, M.D., PhD, DSc, ELIMINATE-B Investigator, Chair Professor of The University of Hong Kong, and the Chief